Amedes acquired MVZ Laaff. All the advisors
Global law firm Clifford Chance has advised amedes Medizinische Dienstleistungen and the investor consortium comprising OMERS Infrastructure, Goldman Sachs Asset Management and AXA IM Alts on shareholder matters relating to amedes’ acquisition of MVZ Laaff.
MVZ Laaff operates medical laboratories at the Freiburg, Heilbronn and Ulm locations with a focus on dermatopathology, general pathology, immunohistology, molecular pathology and cytology.
MVZ Laaff was founded in 1992 by Prof. Dr. Helmut Laaff as Institute for Dermatohistology Pathology Molecular Pathology.
Amedes is a leading German laboratory service provider and operates various medical care centers with different specialist areas across Germany. Work in the medical care centers focusses, among other things, on the areas of laboratory medicine, human genetics, cytology, pathology, gynecology, reproductive medicine and endocrinology.
With the acquisition of MVZ Laaff, amedes intends to strategically strengthen and expand its laboratory services in Baden-Württemberg. The transaction closed in February.
The Clifford Chance team led by partner Mark Aschenbrenner (pictured left) and associate Max Petzelberger (both Private Equity, Munich) comprised partner Anselm Raddatz (Private Equity, Dusseldorf), senior associate Sina Schwirz (Corporate, Munich), partner Dominik Engl (Tax, Frankfurt), partner Katia Gauzès, associates Mélissa Kdyem and Nina Aymé, trainee lawyers Nihad Agadazi and Marie Georg (all Corporate, Luxembourg) as well as partner Jonathan Dillon and senior associate James McMillan (both
Corporate, London).
The amedes in-house team was led by Carolin Tetzel (General Counsel/Legal, pictured right), Dominik Masson (Vice President/M&A), Philip Mertes (Senior Project Manager/M&A) and Sven Breckwold (Senior Project Manager/M&A)
